MAPT and Alzheimer disease: In this study, we report the first ultrasensitive immunoassay for the accurate quantification of phosphorylated tau at threonine 231 in plasma and investigated its potential in multiple scenarios across the AD continuum, primary care utility and against neuropathological confirmation.